1. ALLA AKTIER
  2. NYHETER
  3. NEOLA MEDICAL

Neola Medical

Nyheter Neola Medical Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Neola Medical invites to presentation of the Q3-report 2024

Neola Medical AB (publ) invites to presentation of the Q3-report of 2024, Wednesday the 6th of November 2024 at 09:00 CET (09.00). The presentation will be held online as a webcast hosted by Finwire. The Q3-report will be published the same morning.

Neola Medical publishes the Q3-report in the morning the 6th of November 2024. We hereby invite investors, analysts, and journalists to a combined report presentation and webcast Wednesday the 6th of November 2024 at 09:00 CET (09.00). The report will be presented by CEO Hanna Sjöström and CFO David Folkesson.

Watch the presentation here: https://www.finwire.tv/webcast/neola-medical/q3-2024/ where you also can type in questions in advance and during the presentation that we will be answering live during the Q&A after the presentation.

For further questions after the presentation, contact CFO David Folkesson through below contact details.

The report and report presentation will be available at Neola Medical’s website:
https://www.neolamedical.com/investors/rapporter-och-finansiell-kalender/

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com
David Folkesson, CFO
e-mail: david.folkesson@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical invites to presentation of the Q3-report 2024

Datum 2024-10-30, kl 07:00
Källa MFN
Bifogade filer
Neola Medical invites to presentation of the Q3-report 2024